Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2Hyperglycemia
- Interventions
- Registration Number
- NCT01719003
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
This study will investigate the efficacy and safety of two doses (high and low) of empagliflozin in combination with metformin (500 mg and 1000 mg) administered twice daily in patients with type 2 diabetes mellitus (T2DM). Study will compare four dose combinations of empagliflozin + metformin versus each individual component after 24 weeks of treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1413
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Empagliflozin high dose + met 1000mg bid Empagliflozin high dose bid Empagliflozin high dose split twice daily + metformin 1000 mg twice daily Empagliflozin high dose + met 500 mg bid Metformin 500 mg bid Empagliflozin high dose split twice daily + metformin 500 mg twice daily Empagliflozin low dose + met 1000 mg bid Empagliflozin low dose bid Empagliflozin low dose split twice daily + metformin 1000 mg twice daily OL empa high dose + met 1000 mg bid Empagliflozin high dose bid Open label empagliflozin high dose split twice daily + metformin 1000 mg twice daily - Patients are no longer enrolled into this arm because of change in the inclusion criteria in protocol version 2.0 all patients are now enrolled into remaining double-blind arms. Patients already enrolled in the open-label arm according to protocol version 1.0 can complete the study. OL empa high dose + met 1000 mg bid Metformin 1000 mg bid Open label empagliflozin high dose split twice daily + metformin 1000 mg twice daily - Patients are no longer enrolled into this arm because of change in the inclusion criteria in protocol version 2.0 all patients are now enrolled into remaining double-blind arms. Patients already enrolled in the open-label arm according to protocol version 1.0 can complete the study. Empagliflozin low dose + met 1000 mg bid Metformin 1000 mg bid Empagliflozin low dose split twice daily + metformin 1000 mg twice daily Empagliflozin low dose + met 500 mg bid Metformin 500 mg bid Empagliflozin low dose split twice daily + metformin 500 mg twice daily Empagliflozin high dose + met 1000mg bid Metformin 1000 mg bid Empagliflozin high dose split twice daily + metformin 1000 mg twice daily Metformin 500 mg bid Metformin 500 mg bid Metformin 500 mg twice daily Empagliflozin low dose qd Empagliflozin low dose qd Empagliflozin low dose once daily Empagliflozin high dose qd Empagliflozin high dose qd Empagliflozin high dose once daily Empagliflozin low dose + met 500 mg bid Empagliflozin low dose bid Empagliflozin low dose split twice daily + metformin 500 mg twice daily Empagliflozin high dose + met 500 mg bid Empagliflozin high dose bid Empagliflozin high dose split twice daily + metformin 500 mg twice daily Metformin 1000 mg bid Metformin 1000 mg bid Metformin 1000 mg twice daily
- Primary Outcome Measures
Name Time Method HbA1c (Glycosylated Haemoglobin) Change From Baseline at Week 24 baseline and 24 weeks Change from baseline in HbA1c (%) after 24 weeks of treatment. "Baseline" refers to the last observation before the start of any randomised trial treatment medication. Means presented are the adjusted means
- Secondary Outcome Measures
Name Time Method FPG (Fasting Plasma Glucose) Change From Baseline at Week 24 baseline and 24 weeks Change from baseline in FPG (mg/dL) after 24 weeks of treatment. "Baseline" refers to the last observation before the start of any randomised trial treatment medication. Means presented are the adjusted means.
Body Weight Change From Baseline at Week 24 baseline and 24 weeks Change from baseline in body weight (kg) after 24 weeks of treatment. "Baseline" refers to the last observation before the start of any randomised trial treatment. medication. Means presented are the adjusted means.
Trial Locations
- Locations (190)
1276.1.10010 Boehringer Ingelheim Investigational Site
πΊπΈGlendale, Arizona, United States
1276.1.10008 Boehringer Ingelheim Investigational Site
πΊπΈGreer, South Carolina, United States
1276.1.50005 Boehringer Ingelheim Investigational Site
π¬πΉGuatemala, Guatemala
1276.1.50006 Boehringer Ingelheim Investigational Site
π¬πΉGuatemala, Guatemala
1276.1.60001 Boehringer Ingelheim Investigational Site
π²πΎJohor Bahru, Malaysia
1276.1.51004 Boehringer Ingelheim Investigational Site
π΅πͺLima, Peru
1276.1.63009 Boehringer Ingelheim Investigational Site
π΅πCebu City, Cebu, Philippines
1276.1.63006 Boehringer Ingelheim Investigational Site
π΅πManila, Philippines
1276.1.63001 Boehringer Ingelheim Investigational Site
π΅πMarikina City, Philippines
1276.1.63007 Boehringer Ingelheim Investigational Site
π΅πSan Juan City, Philippines
1276.1.63008 Boehringer Ingelheim Investigational Site
π΅πTarlac, Philippines
1276.1.70018 Boehringer Ingelheim Investigational Site
π·πΊNovosibirsk, Russian Federation
1276.1.70007 Boehringer Ingelheim Investigational Site
π·πΊPetrozavodsk, Russian Federation
1276.1.38103 Boehringer Ingelheim Investigational Site
π·πΈKragujevac, Serbia
1276.1.38102 Boehringer Ingelheim Investigational Site
π·πΈZajecar, Serbia
1276.1.88005 Boehringer Ingelheim Investigational Site
π¨π³Kaohsiung City,, Taiwan
1276.1.88002 Boehringer Ingelheim Investigational Site
π¨π³New Taipei City, Taiwan
1276.1.66003 Boehringer Ingelheim Investigational Site
πΉπBangkok, Thailand, Thailand
1276.1.90003 Boehringer Ingelheim Investigational Site
πΉπ·Ankara, Turkey
1276.1.66001 Boehringer Ingelheim Investigational Site
πΉπBangkok, Thailand, Thailand
1276.1.88006 Boehringer Ingelheim Investigational Site
π¨π³Taipei, Taiwan
1276.1.66002 Boehringer Ingelheim Investigational Site
πΉπNakhon Ratchasima, Thailand
1276.1.10032 Boehringer Ingelheim Investigational Site
πΊπΈFall River, Massachusetts, United States
1276.1.10023 Boehringer Ingelheim Investigational Site
πΊπΈMarietta, Georgia, United States
1276.1.10030 Boehringer Ingelheim Investigational Site
πΊπΈColumbia, South Carolina, United States
1276.1.96004 Boehringer Ingelheim Investigational Site
π±π§Saida, Lebanon
1276.1.20001 Boehringer Ingelheim Investigational Site
π¨π¦Saskatoon, Saskatchewan, Canada
1276.1.20007 Boehringer Ingelheim Investigational Site
π¨π¦Mirabel, Quebec, Canada
1276.1.42002 Boehringer Ingelheim Investigational Site
π¨πΏBenatky nad Jizerou, Czech Republic
1276.1.42010 Boehringer Ingelheim Investigational Site
π¨πΏPraha 1, Czech Republic
1276.1.95003 Boehringer Ingelheim Investigational Site
πͺπ¬Al Manial, Cairo, Egypt, Egypt
1276.1.10044 Boehringer Ingelheim Investigational Site
πΊπΈHot Springs, Alaska, United States
1276.1.10046 Boehringer Ingelheim Investigational Site
πΊπΈChula Vista, California, United States
1276.1.10006 Boehringer Ingelheim Investigational Site
πΊπΈHuntington Beach, California, United States
1276.1.10035 Boehringer Ingelheim Investigational Site
πΊπΈSearcy, Arkansas, United States
1276.1.10009 Boehringer Ingelheim Investigational Site
πΊπΈLos Angeles, California, United States
1276.1.10043 Boehringer Ingelheim Investigational Site
πΊπΈLa Mesa, California, United States
1276.1.10045 Boehringer Ingelheim Investigational Site
πΊπΈOceanside, California, United States
1276.1.10040 Boehringer Ingelheim Investigational Site
πΊπΈLos Angeles, California, United States
1276.1.10024 Boehringer Ingelheim Investigational Site
πΊπΈOldsmar, Florida, United States
1276.1.10026 Boehringer Ingelheim Investigational Site
πΊπΈFort Lauderdale, Florida, United States
1276.1.10003 Boehringer Ingelheim Investigational Site
πΊπΈNorthglenn, Colorado, United States
1276.1.10027 Boehringer Ingelheim Investigational Site
πΊπΈPort Orange, Florida, United States
1276.1.20002 Boehringer Ingelheim Investigational Site
π¨π¦Quebec, Canada
1276.1.10034 Boehringer Ingelheim Investigational Site
πΊπΈEvansville, Indiana, United States
1276.1.10015 Boehringer Ingelheim Investigational Site
πΊπΈUnion, New Jersey, United States
1276.1.10036 Boehringer Ingelheim Investigational Site
πΊπΈBridgman, Michigan, United States
1276.1.10037 Boehringer Ingelheim Investigational Site
πΊπΈHazelwood, Missouri, United States
1276.1.10033 Boehringer Ingelheim Investigational Site
πΊπΈAsheboro, North Carolina, United States
1276.1.10022 Boehringer Ingelheim Investigational Site
πΊπΈBurlington, North Carolina, United States
1276.1.10011 Boehringer Ingelheim Investigational Site
πΊπΈGallipolis, Ohio, United States
1276.1.10002 Boehringer Ingelheim Investigational Site
πΊπΈLenoir, North Carolina, United States
1276.1.10013 Boehringer Ingelheim Investigational Site
πΊπΈHodges, South Carolina, United States
1276.1.10018 Boehringer Ingelheim Investigational Site
πΊπΈHouston, Texas, United States
1276.1.10017 Boehringer Ingelheim Investigational Site
πΊπΈHumboldt, Tennessee, United States
1276.1.10016 Boehringer Ingelheim Investigational Site
πΊπΈKingwood, Texas, United States
1276.1.10025 Boehringer Ingelheim Investigational Site
πΊπΈHouston, Texas, United States
1276.1.10028 Boehringer Ingelheim Investigational Site
πΊπΈHouston, Texas, United States
1276.1.10012 Boehringer Ingelheim Investigational Site
πΊπΈWenatchee, Washington, United States
1276.1.10004 Boehringer Ingelheim Investigational Site
πΊπΈManassas, Virginia, United States
1276.1.55008 Boehringer Ingelheim Investigational Site
π§π·BelΓ©m, Brazil
1276.1.55003 Boehringer Ingelheim Investigational Site
π§π·Brasilia, Brazil
1276.1.55004 Boehringer Ingelheim Investigational Site
π§π·Goiania, Brazil
1276.1.55006 Boehringer Ingelheim Investigational Site
π§π·Fortaleza, Brazil
1276.1.55007 Boehringer Ingelheim Investigational Site
π§π·Fortaleza, Brazil
1276.1.55009 Boehringer Ingelheim Investigational Site
π§π·Fortaleza, Brazil
1276.1.55002 Boehringer Ingelheim Investigational Site
π§π·Porto Alegre, Brazil
1276.1.55001 Boehringer Ingelheim Investigational Site
π§π·Sao Paulo, Brazil
1276.1.20003 Boehringer Ingelheim Investigational Site
π¨π¦Coquitlam, British Columbia, Canada
1276.1.20012 Boehringer Ingelheim Investigational Site
π¨π¦Coquitlam, British Columbia, Canada
1276.1.20008 Boehringer Ingelheim Investigational Site
π¨π¦Victoria, British Columbia, Canada
1276.1.20005 Boehringer Ingelheim Investigational Site
π¨π¦Hawkesbury, Ontario, Canada
1276.1.20004 Boehringer Ingelheim Investigational Site
π¨π¦Antigonish, Nova Scotia, Canada
1276.1.20010 Boehringer Ingelheim Investigational Site
π¨π¦Strathroy, Ontario, Canada
1276.1.20006 Boehringer Ingelheim Investigational Site
π¨π¦Thornhill, Ontario, Canada
1276.1.20013 Boehringer Ingelheim Investigational Site
π¨π¦Sarnia, Ontario, Canada
1276.1.42008 Boehringer Ingelheim Investigational Site
π¨πΏOlomouc, Czech Republic
1276.1.42004 Boehringer Ingelheim Investigational Site
π¨πΏPraha 10, Czech Republic
1276.1.42007 Boehringer Ingelheim Investigational Site
π¨πΏOstrava, Czech Republic
1276.1.42009 Boehringer Ingelheim Investigational Site
π¨πΏPlzen, Czech Republic
1276.1.42003 Boehringer Ingelheim Investigational Site
π¨πΏPraha 3, Czech Republic
1276.1.95004 Boehringer Ingelheim Investigational Site
πͺπ¬Alexandria, Egypt
1276.1.95001 Boehringer Ingelheim Investigational Site
πͺπ¬Abbasia Cairo, Egypt, Egypt
1276.1.95002 Boehringer Ingelheim Investigational Site
πͺπ¬El Darasa Cairo Egypt, Egypt
1276.1.33004 Boehringer Ingelheim Investigational Site
π«π·Behren Les Forbach, France
1276.1.33012 Boehringer Ingelheim Investigational Site
π«π·BersΓ©e, France
1276.1.33007 Boehringer Ingelheim Investigational Site
π«π·Hautmont, France
1276.1.33001 Boehringer Ingelheim Investigational Site
π«π·Poitiers, France
1276.1.33003 Boehringer Ingelheim Investigational Site
π«π·SavonniΓ¨res, France
1276.1.33013 Boehringer Ingelheim Investigational Site
π«π·Paris, France
1276.1.33002 Boehringer Ingelheim Investigational Site
π«π·Thouars, France
1276.1.33006 Boehringer Ingelheim Investigational Site
π«π·St Genis des Fontaines, France
1276.1.33011 Boehringer Ingelheim Investigational Site
π«π·Thun St amand, France
1276.1.33010 Boehringer Ingelheim Investigational Site
π«π·Tours, France
1276.1.33008 Boehringer Ingelheim Investigational Site
π«π·Vieux CondΓ©, France
1276.1.33009 Boehringer Ingelheim Investigational Site
π«π·Vandome, France
1276.1.49005 Boehringer Ingelheim Investigational Site
π©πͺBerlin, Germany
1276.1.49008 Boehringer Ingelheim Investigational Site
π©πͺCelle, Germany
1276.1.49006 Boehringer Ingelheim Investigational Site
π©πͺDortmund, Germany
1276.1.49011 Boehringer Ingelheim Investigational Site
π©πͺDresden, Germany
1276.1.49003 Boehringer Ingelheim Investigational Site
π©πͺEssen, Germany
1276.1.49014 Boehringer Ingelheim Investigational Site
π©πͺNeuwied, Germany
1276.1.49002 Boehringer Ingelheim Investigational Site
π©πͺStuhr-Brinkum, Germany
1276.1.49004 Boehringer Ingelheim Investigational Site
π©πͺOffenbach, Germany
1276.1.50002 Boehringer Ingelheim Investigational Site
π¬πΉBarbena Santa Rosa, Guatemala
1276.1.49012 Boehringer Ingelheim Investigational Site
π©πͺTeuchern, Germany
1276.1.50003 Boehringer Ingelheim Investigational Site
π¬πΉGuatemala, Guatemala
1276.1.50001 Boehringer Ingelheim Investigational Site
π¬πΉQuetzaltenango, Guatemala
1276.1.82006 Boehringer Ingelheim Investigational Site
π°π·Deagu, Korea, Republic of
1276.1.82010 Boehringer Ingelheim Investigational Site
π°π·Goyang, Korea, Republic of
1276.1.82009 Boehringer Ingelheim Investigational Site
π°π·Pusan, Korea, Republic of
1276.1.82004 Boehringer Ingelheim Investigational Site
π°π·Seoul, Korea, Republic of
1276.1.82005 Boehringer Ingelheim Investigational Site
π°π·Seoul, Korea, Republic of
1276.1.96002 Boehringer Ingelheim Investigational Site
π±π§El Chouf, Lebanon
1276.1.82007 Boehringer Ingelheim Investigational Site
π°π·Seoul, Korea, Republic of
1276.1.82002 Boehringer Ingelheim Investigational Site
π°π·Seoul, Korea, Republic of
1276.1.96001 Boehringer Ingelheim Investigational Site
π±π§Beirut, Lebanon
1276.1.96003 Boehringer Ingelheim Investigational Site
π±π§Saida, Lebanon
1276.1.82003 Boehringer Ingelheim Investigational Site
π°π·Wonju, Korea, Republic of
1276.1.82008 Boehringer Ingelheim Investigational Site
π°π·Seoul, Korea, Republic of
1276.1.60002 Boehringer Ingelheim Investigational Site
π²πΎIpoh, Perak, Malaysia
1276.1.60003 Boehringer Ingelheim Investigational Site
π²πΎKubang Kerian, Malaysia
1276.1.52004 Boehringer Ingelheim Investigational Site
π²π½Aguascalientes, Mexico
1276.1.52002 Boehringer Ingelheim Investigational Site
π²π½Ciudad de Mexico, Mexico
1276.1.52003 Boehringer Ingelheim Investigational Site
π²π½Guadalajara, Mexico
1276.1.52007 Boehringer Ingelheim Investigational Site
π²π½Aguascalientes, Mexico
1276.1.52005 Boehringer Ingelheim Investigational Site
π²π½Zapopan, Mexico
1276.1.52001 Boehringer Ingelheim Investigational Site
π²π½Monterrey, Mexico
1276.1.52006 Boehringer Ingelheim Investigational Site
π²π½San Lucas tepetlcalco, Mexico
1276.1.51001 Boehringer Ingelheim Investigational Site
π΅πͺLima, Peru
1276.1.51003 Boehringer Ingelheim Investigational Site
π΅πͺLima, Peru
1276.1.51005 Boehringer Ingelheim Investigational Site
π΅πͺLima, Peru
1276.1.63002 Boehringer Ingelheim Investigational Site
π΅πCebu City, Philippines, Philippines
1276.1.70017 Boehringer Ingelheim Investigational Site
π·πΊSt. Petersburg, Russian Federation
1276.1.34027 Boehringer Ingelheim Investigational Site
πͺπΈSalamanca, Spain
1276.1.90006 Boehringer Ingelheim Investigational Site
πΉπ·Denizli, Turkey
1276.1.90001 Boehringer Ingelheim Investigational Site
πΉπ·Izmir, Turkey
1276.1.44006 Boehringer Ingelheim Investigational Site
π¬π§Dagenham, United Kingdom
1276.1.44003 Boehringer Ingelheim Investigational Site
π¬π§Leeds, United Kingdom
1276.1.44007 Boehringer Ingelheim Investigational Site
π¬π§Manchester, United Kingdom
1276.1.44004 Boehringer Ingelheim Investigational Site
π¬π§Doncaster, United Kingdom
1276.1.44011 Boehringer Ingelheim Investigational Site
π¬π§Mortimer, United Kingdom
1276.1.44009 Boehringer Ingelheim Investigational Site
π¬π§Sandbach, United Kingdom
1276.1.10042 Boehringer Ingelheim Investigational Site
πΊπΈColorado Springs, Colorado, United States
1276.1.33005 Boehringer Ingelheim Investigational Site
π«π·Cournonterral, France
1276.1.82001 Boehringer Ingelheim Investigational Site
π°π·Incheon, Korea, Republic of
1276.1.10019 Boehringer Ingelheim Investigational Site
πΊπΈBirmingham, Alabama, United States
1276.1.10014 Boehringer Ingelheim Investigational Site
πΊπΈBirmingham, Alabama, United States
1276.1.10001 Boehringer Ingelheim Investigational Site
πΊπΈDenver, Colorado, United States
1276.1.10007 Boehringer Ingelheim Investigational Site
πΊπΈLas Vegas, Nevada, United States
1276.1.10005 Boehringer Ingelheim Investigational Site
πΊπΈCincinnati, Ohio, United States
1276.1.10021 Boehringer Ingelheim Investigational Site
πΊπΈSan Antonio, Texas, United States
1276.1.10041 Boehringer Ingelheim Investigational Site
πΊπΈSan Antonio, Texas, United States
1276.1.49007 Boehringer Ingelheim Investigational Site
π©πͺIngelheim, Germany
1276.1.51002 Boehringer Ingelheim Investigational Site
π΅πͺLima, Peru
1276.1.63004 Boehringer Ingelheim Investigational Site
π΅πDavao City, Philippines
1276.1.63003 Boehringer Ingelheim Investigational Site
π΅πIloilo City, Philippines
1276.1.63005 Boehringer Ingelheim Investigational Site
π΅πMaybunga, Pasig City, Philippines
1276.1.70012 Boehringer Ingelheim Investigational Site
π·πΊBarnaul, Russian Federation
1276.1.38101 Boehringer Ingelheim Investigational Site
π·πΈNis, Serbia
1276.1.88001 Boehringer Ingelheim Investigational Site
π¨π³Taichung, Taiwan
1276.1.34050 Boehringer Ingelheim Investigational Site
πͺπΈAlzira, Spain
1276.1.34052 Boehringer Ingelheim Investigational Site
πͺπΈTarragona, Spain
1276.1.70011 Boehringer Ingelheim Investigational Site
π·πΊKemerovo, Russian Federation
1276.1.44005 Boehringer Ingelheim Investigational Site
π¬π§Chippenham, United Kingdom
1276.1.34051 Boehringer Ingelheim Investigational Site
πͺπΈZaragoza, Spain
1276.1.70015 Boehringer Ingelheim Investigational Site
π·πΊNovosibirsk, Russian Federation
1276.1.70013 Boehringer Ingelheim Investigational Site
π·πΊYaroslavl, Russian Federation
1276.1.38105 Boehringer Ingelheim Investigational Site
π·πΈBelgrade, Serbia
1276.1.38106 Boehringer Ingelheim Investigational Site
π·πΈBelgrade, Serbia
1276.1.38107 Boehringer Ingelheim Investigational Site
π·πΈBelgrade, Serbia
1276.1.34045 Boehringer Ingelheim Investigational Site
πͺπΈpozuelo de Alarcon, Spain
1276.1.34028 Boehringer Ingelheim Investigational Site
πͺπΈMadrid, Spain
1276.1.70016 Boehringer Ingelheim Investigational Site
π·πΊNovosibirsk, Russian Federation
1276.1.70009 Boehringer Ingelheim Investigational Site
π·πΊSaratov, Russian Federation
1276.1.70010 Boehringer Ingelheim Investigational Site
π·πΊSmolensk, Russian Federation
1276.1.70005 Boehringer Ingelheim Investigational Site
π·πΊSt. Petersburg, Russian Federation
1276.1.38104 Boehringer Ingelheim Investigational Site
π·πΈBelgrade, Serbia
1276.1.88003 Boehringer Ingelheim Investigational Site
π¨π³Taichung, Taiwan
1276.1.70006 Boehringer Ingelheim Investigational Site
π·πΊSt. Petersburg, Russian Federation
1276.1.38108 Boehringer Ingelheim Investigational Site
π·πΈNovi Sad, Serbia
1276.1.34048 Boehringer Ingelheim Investigational Site
πͺπΈAlicante, Spain
1276.1.88004 Boehringer Ingelheim Investigational Site
π¨π³Taichung, Taiwan
1276.1.90004 Boehringer Ingelheim Investigational Site
πΉπ·Antalya, Turkey
1276.1.90002 Boehringer Ingelheim Investigational Site
πΉπ·Erzurum, Turkey
1276.1.90005 Boehringer Ingelheim Investigational Site
πΉπ·Istanbul, Turkey
1276.1.44002 Boehringer Ingelheim Investigational Site
π¬π§Bolton, United Kingdom
1276.1.44001 Boehringer Ingelheim Investigational Site
π¬π§Bradford on Avon, United Kingdom
1276.1.44008 Boehringer Ingelheim Investigational Site
π¬π§Glasgow, United Kingdom
1276.1.34034 Boehringer Ingelheim Investigational Site
πͺπΈSabadell (Barcelona), Spain